Big Pharma's Pricing Power Imperiled By Part D Overhaul

Law360, New York (January 14, 2014, 4:46 PM EST) -- Drugmakers will lose major leverage with private insurers in their pricing of products supplied through Medicare Part D if federal regulators follow through on new plans to eliminate mandatory coverage requirements, experts say.

The policy overhaul, which some patient advocates have already decried, would do away with up to three of six “protected classes” that force insurance companies to cover virtually all drugs in various categories.

“To me, this is the most significant change that has been made in Part D since the program began,” with...
To view the full article, register now.